Prevalence and Penetrance of Rare Pathogenic Variants in Neurodevelopmental Psychiatric Genes in a Health Care System Population.

OBJECTIVE Autism, schizophrenia, and other clinically distinct neurodevelopmental psychiatric disorders (NPDs) have shared genetic etiologies, including single-gene and multigenic copy number variants (CNVs). Because rare variants are primarily investigated in clinical cohorts, population-based estimates of their prevalence and penetrance are lacking. The authors determined the prevalence, penetrance, and NPD risk of pathogenic single-gene variants in a large health care system population. METHODS The authors analyzed linked genomic and electronic health record (EHR) data in a subset of 90,595 participants from Geisinger's MyCode Community Health Initiative, known as the DiscovEHR cohort. Loss-of-function pathogenic variants in 94 high-confidence NPD genes were identified through exome sequencing, and NPD penetrance was calculated using preselected EHR diagnosis codes. NPD risk was estimated using a case-control comparison of DiscovEHR participants with and without NPD diagnoses. Results from single-gene variant analyses were also compared with those from 31 previously reported pathogenic NPD CNVs. RESULTS Pathogenic variants were identified in 0.34% of the DiscovEHR cohort and demonstrated a 34.3% penetrance for NPDs. Similar to CNVs, sequence variants collectively conferred a substantial risk for several NPD diagnoses, including autism, schizophrenia, and bipolar disorder. Significant NPD risk remained after participants with intellectual disability were excluded from the analysis, confirming the association with major psychiatric disorders in individuals without severe cognitive deficits. CONCLUSIONS Collectively, rare single-gene variants and CNVs were found in >1% of individuals in a large health care system population and play an important contributory role in mental health disorders. Diagnostic genetic testing for pathogenic variants among symptomatic individuals with NPDs could improve clinical outcomes through early intervention and anticipatory therapeutic support.

[1]  D. Ledbetter,et al.  Medical manifestations and healthcare utilization among adult MyCode participants with neurodevelopmental psychiatric copy number variants , 2021, Genetics in Medicine.

[2]  D. Ledbetter,et al.  Population Genomic Screening for Genetic Etiologies of Neurodevelopmental/Psychiatric Disorders Demonstrates Personal Utility and Positive Participant Responses , 2021, Journal of personalized medicine.

[3]  D. Ledbetter,et al.  Diagnostic genetic testing for neurodevelopmental psychiatric disorders: closing the gap between recommendation and clinical implementation. , 2021, Current opinion in genetics & development.

[4]  D. Ledbetter,et al.  Identification of Neuropsychiatric Copy Number Variants in a Health Care System Population , 2020, JAMA psychiatry.

[5]  Janice M. Fullerton,et al.  De Novo Gene Variants and Familial Bipolar Disorder , 2020, JAMA network open.

[6]  M. Daly,et al.  Exome sequencing in schizophrenia-affected parent-offspring trios reveals risk conferred by protein-coding de novo mutations , 2019, Nature Neuroscience.

[7]  Ryan L. Collins,et al.  The mutational constraint spectrum quantified from variation in 141,456 humans , 2020, Nature.

[8]  P. Pavlidis,et al.  VariCarta: A Comprehensive Database of Harmonized Genomic Variants Found in Autism Spectrum Disorder Sequencing Studies , 2019, Autism research : official journal of the International Society for Autism Research.

[9]  S. South,et al.  Technical standards for the interpretation and reporting of constitutional copy number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen) , 2019, Genetics in Medicine.

[10]  L. Schieve,et al.  Prevalence and Trends of Developmental Disabilities among Children in the United States: 2009–2017 , 2019, Pediatrics.

[11]  Laura Pérez-Cano,et al.  Inherited and De Novo Genetic Risk for Autism Impacts Shared Networks , 2019, Cell.

[12]  Guan Ning Lin,et al.  De novo Mutations From Whole Exome Sequencing in Neurodevelopmental and Psychiatric Disorders: From Discovery to Application , 2019, Front. Genet..

[13]  Michael R. Johnson,et al.  Ultra-rare genetic variation in the epilepsies: a whole-exome sequencing study of 17,606 individuals , 2019, bioRxiv.

[14]  Caroline F. Wright,et al.  Assessing the Pathogenicity, Penetrance, and Expressivity of Putative Disease-Causing Variants in a Population Setting , 2018, bioRxiv.

[15]  Bradley P. Coe,et al.  Genome sequencing identifies multiple deleterious variants in autism patients with more severe phenotypes , 2018, Genetics in Medicine.

[16]  P. Donnelly,et al.  The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[17]  Marina T. DiStefano,et al.  Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion , 2018, Human mutation.

[18]  N. Hollis,et al.  Prevalence of Disabilities and Health Care Access by Disability Status and Type Among Adults — United States, 2016 , 2018, MMWR. Morbidity and mortality weekly report.

[19]  Alicia R. Martin,et al.  Quantifying the Impact of Rare and Ultra-rare Coding Variation across the Phenotypic Spectrum. , 2018, American journal of human genetics.

[20]  G. Kirov,et al.  Medical consequences of pathogenic CNVs in adults: analysis of the UK Biobank , 2018, Journal of Medical Genetics.

[21]  I. Scheffer,et al.  A case-control collapsing analysis identifies epilepsy genes implicated in trio sequencing studies focused on de novo mutations , 2017, PLoS genetics.

[22]  Alexander E. Lopez,et al.  Profiling and leveraging relatedness in a precision medicine cohort of 92,455 exomes , 2017, bioRxiv.

[23]  Hoang T. Nguyen,et al.  Integrated Bayesian analysis of rare exonic variants to identify risk genes for schizophrenia and neurodevelopmental disorders , 2017, Genome Medicine.

[24]  Elvira Bramon,et al.  The contribution of rare variants to risk of 1 schizophrenia in individuals with and without 2 intellectual disability , 2017 .

[25]  G. Barsh,et al.  Genomic diagnosis for children with intellectual disability and/or developmental delay , 2017, Genome Medicine.

[26]  Deciphering Developmental Disorders Study,et al.  Prevalence and architecture of de novo mutations in developmental disorders , 2017, Nature.

[27]  Marylyn D. Ritchie,et al.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.

[28]  L. Vissers,et al.  Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability , 2016, Nature Neuroscience.

[29]  N. Matoba,et al.  Exome sequencing for bipolar disorder points to roles of de novo loss-of-function and protein-altering mutations , 2016, Molecular Psychiatry.

[30]  Christa Lese Martin,et al.  A Cross-Disorder Method to Identify Novel Candidate Genes for Developmental Brain Disorders. , 2016, JAMA psychiatry.

[31]  D. Ledbetter,et al.  The Geisinger MyCode Community Health Initiative: an electronic health record-linked biobank for Precision Medicine research , 2015, Genetics in Medicine.

[32]  D. Ledbetter,et al.  Shift happens: family background influences clinical variability in genetic neurodevelopmental disorders , 2015, Genetics in Medicine.

[33]  Tom R. Gaunt,et al.  Copy number variations and cognitive phenotypes in unselected populations. , 2015, JAMA.

[34]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[35]  David W. Evans,et al.  The role of parental cognitive, behavioral, and motor profiles in clinical variability in individuals with chromosome 16p11.2 deletions. , 2015, JAMA psychiatry.

[36]  Boris Yamrom,et al.  The contribution of de novo coding mutations to autism spectrum disorder , 2014, Nature.

[37]  Jay Shendure,et al.  Disruptive CHD8 Mutations Define a Subtype of Autism Early in Development , 2014, Cell.

[38]  Adam J. Schwarz,et al.  CNVs conferring risk of autism or schizophrenia affect cognition in controls , 2013, Nature.

[39]  Sharmila Banerjee-Basu,et al.  SFARI Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs) , 2013, Molecular Autism.